Biogen (BIIB) Says First Phase 3 Trial for Oral BG-12 Met Primary Endpoint and All Secondary Endpoints
Go back to Biogen (BIIB) Says First Phase 3 Trial for Oral BG-12 Met Primary Endpoint and All Secondary Endpoints| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 217.11 +2.76 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $214.35 | 52 Week High | $333.65 | |||
| Open | $217.76 | 52 Week Low | $223.02 | |||
| Day High | $219.12 | P/E | 27.80 | |||
| Day Low | $215.00 | EPS | $7.81 | |||
| Volume | 366,527 | |||||
